Parathyroid Hormone Resistance and Bilateral Macronodular Adrenocortical Disease: Does Partial Loss of Methylation at the GNAS Exon 1 Differentially Methylated Region (DMR) Play a Role?

Key words

hyperparathyroidism - pseudohypoparathyroidism - adrenal tumor - methylation - GNAS

• References

• 1 Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes 2012; 19: 443-451
• 2 Almeida MQ, Azevedo MF, Xekouki P, Bimpaki EI, Horvath A, Collins MT, Karaviti LP, Jeha GS, Bhattacharyya N, Cheadle C, Watkins T, Bourdeau I, Nesterova M, Stratakis CA. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J Clin Endocrinol Metab 2012; 97: E687-E693
• 3 Nakajima Y, Okamura T, Horiguchi K, Gohko T, Miyamoto T, Satoh T, Ozawa A, Ishii S, Yamada E, Hashimoto K, Okada S, Takata D, Horiguchi J, Yamada M. GNAS mutations in adrenal aldosterone-producing adenomas. Endocr J 2016; 63: 199-204
• 4 Mazzuco TL, Grunenwald S, Lampron A, Bourdeau I, Lacroix A. Aberrant hormone receptors in primary aldosteronism. Horm Metab Res 2010; 42: 416-423
• 5 Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2010; 73: 1-15
• 6 Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002; 87: 5367-5384
• 7 Rochtus A, Martin-Trujillo A, Izzi B, Elli F, Garin I, Linglart A, Mantovani G, Perez de Nanclares G, Thiele S, Decallonne B, Van Geet C, Monk D, Freson K. Genome-wide DNA methylation analysis of pseudohypoparathyroidism patients with GNAS imprinting defects. Clin Epigenetics 2016; 8: 10
• 8 Garin I, Mantovani G, Aguirre U, Barlier A, Brix B, Elli FM, Freson K, Grybek V, Izzi B, Linglart A, Perez de Nanclares G, Silve C, Thiele S, Werner R. EuroPHP Consortium. European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: an EQA study. Eur J Hum Genet 2015; 23: 438-444
• 9 Cavalier E, Carlisi A, Chapelle JP, Orfanos P, Uzan M, Falque V, Delanaye P, Hachicha M. Human anti-mouse antibodies interferences in Elecsys PTH assay after OKT3 treatment. Transplantation 2009; 87: 451-452
• 10 Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34
• 11 Mantovani G, Elli FM, Spada A. GNAS epigenetic defects and pseudohypoparathyroidism: time for a new classification?. Horm Metab Res 2012; 44: 716-723
• 12 Nakamura A, Hamaguchi E, Horikawa R, Nishimura Y, Matsubara K, Sano S, Nagasaki K, Matsubara Y, Umezawa A, Tajima T, Ogata T, Kagami M, Okamura K, Fukami M. Complex genomic rearrangement within the gnas region associated with familial pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab 2016; 101: 2623-2627
• 13 Court F, Martin-Trujillo A, Romanelli V, Garin I, Iglesias-Platas I, Salafsky I, Guitart M, Perez de Nanclares G, Lapunzina P, Monk D. Genome-wide allelic methylation analysis reveals disease-specific susceptibility to multiple methylation defects in imprinting syndromes. Hum Mutat 2013; 34: 595-602
• 14 Kiedrowicz B, Binczak-Kuleta A, Lubikowski J, Koziolek M, Andrysiak-Mamos E, Ostanek-Panka M, Ciechanowicz A, Syrenicz A. Prevalence and clinical outcome of cyp21a2 gene mutations in patients with nonfunctional adrenal incidentalomas. Horm Metab Res 2015; 47: 662-667
• 15 Bertoin F, Letouzé E, Grignani P, Patey M, Rossignol S, Libé R, Pasqual C, Lardière-Deguelte S, Hoeffel-Fornes C, Gaillard D, Previderè C, Delemer B, Lalli E. Genome-wide paternal uniparental disomy as a cause of Beckwith-Wiedemann syndrome associated with recurrent virilizing adrenocortical tumors. Horm Metab Res 2015; 47: 497-503
• 16 Moors M, Williams TA, Deinum J, Eisenhofer G, Reincke M, Lenders JW. Steroid hormone production in patients with aldosterone producing adenomas. Horm Metab Res 2015; 47: 967-972
• 17 Zennaro MC, Fernandes-Rosa F, Boulkroun S, Jeunemaitre X. Bilateral idiopathic adrenal hyperplasia: genetics and beyond. Horm Metab Res 2015; 47: 947-952
• 18 Angelousi A, Fencl F, Faucz FR, Malikova J, Sumnik Z, Lebl J, Stratakis CA. McCune Albright syndrome and bilateral adrenal hyperplasia: the GNAS mutation may only be present in adrenal tissue. Hormones (Athens) 2015; 14: 447-450
• 19 Sidhu A, Debelenko L, Misra VK. Infantile adrenocortical tumor with an activating GNAS1 mutation. J Clin Endocrinol Metab 2013; 98: E115-E118
• 20 Kool MM, Galac S, Spandauw CG, Kooistra HS, Mol JA. Activating mutations of GNAS in canine cortisol-secreting adrenocortical tumors. J Vet Intern Med 2013; 27: 1486-1492
• 21 Szarek E, Stratakis CA. Phosphodiesterases and adrenal Cushing in mice and humans. Horm Metab Res 2014; 46: 863-868
• 22 Muscogiuri G, Altieri B, Penna-Martinez M, Badenhoop K. Focus on vitamin D and the adrenal gland. Horm Metab Res 2015; 47: 239-246
• 23 Chrysostomou PP, Lodish MB, Turkbey EB, Papadakis GZ, Stratakis CA. Use of 3-dimensional volumetric modeling of adrenal gland size in patients with primary pigmented nodular adrenocortical disease. Horm Metab Res 2016; 48: 242-246
• 24 Weinstein LS. Role of G(s)a in central regulation of energy and glucose metabolism. Horm Metab Res 2014; 46: 841-844
• 25 Roizen JD, Danzig J, Groleau V, McCormack S, Casella A, Harrington J, Sochett E, Tershakovec A, Zemel BS, Stallings VA, Levine MA. Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A. J Clin Endocrinol Metab 2016; 101: 880-808